Form 8-K 2seventy bio, Inc. For: Nov 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Goldman Sachs Reiterates Sell Rating on 2Seventy Bio Inc. (TSVT)
November 12, 2024 12:52 PM ESTGoldman Sachs analyst Salveen Richter reiterated a Sell rating and $2.00 price target on 2Seventy Bio Inc. (NASDAQ: TSVT).
The analyst comments "TSVT reported 3Q US Abecma sales of $77mn (as reported by partner BMY) vs. GSe/Visible Alpha consensus of $70mn/$70mn, with Abecma profit-share of $11mn (vs. GSe/consesnus of $7mn/$11mn); GAAP EPS of ($0.19) was in line with consensus of ($0.19) (vs. GSe of ($0.34); Exhibit 1). While 3Q Abecma... More
